| This week's sponsor is Premier Research. | |  | Immunotherapy: Unleashing the Body's Potential to Fight Cancer
The immune system's role in fighting cancer becomes clearer every day, and the therapeutic implications are enormous. Discover promising new approaches to immunotherapy in our new white paper.
Premier Research. It's what we do. Best. |
Featured Story | | | Tuesday, June 20, 2017 EvaluatePharma says spending on global pharma research will hit $181 billion in five years as Roche, AbbVie and AstraZeneca are seen as having some of the biggest potential pipeline medications. |
|
|
| This week's sponsor is Myriad RBM. | |  | |
Top Stories Tuesday, June 20, 2017 After growing rumors this week, Parexel has become the latest CRO to be bought up as the industry continues its M&A bonanza. Tuesday, June 20, 2017 German Merck, fresh off it and partner Pfizer’s FDA approval for their checkpoint inhibitor Bavencio, and R&D charity CRUK are coming together to launch a new IO-focused biotech. Monday, June 19, 2017 How PAREXEL's New Ecosystem of Technology, Processes and Expertise is Transforming Drug Development Tuesday, June 20, 2017 Cell Medica has bought Catapult Therapy TCR for its clinical-phase WT1 T-cell receptor (TCR) cell therapy. Catapult Therapy TCR developed the therapy as a treatment for blood cancers, but Cell Medica thinks it can retool it to take out solid tumors. Tuesday, June 20, 2017 Filings for brolucizumab are expected next year, with analysts at Jefferies predicting $2 billion in peak sales for the drug. Tuesday, June 20, 2017 Akcea Therapeutics is closing in on an IPO expected to gross in the region of $125 million. The Ionis Pharmaceuticals’ lipid disorder subsidiary plans to spend most of the money on the generation of phase 3 data to support the approval of volanesorsen in two indications. Monday, June 19, 2017 The quest to inhibit the cholesterol-related enzyme PCSK9 has produced two high-profile drugs and a massive patent battle between their makers. Now a group of scientists in Europe, along with the biotech company Affiris, are proposing a different way to inhibit PCSK9—with a vaccine that they say showed promising results in mice. | This week's sponsor is J.P. Morgan Private Bank. | |  | How Your Assets Are Structured Can Have Long-Term Implications On Your Wealth
As a founder or executive of a healthcare business, it's crucial your assets are titled properly. J.P. Morgan Private Bank knows how to protect your assets and preserve your wealth. Download this article on asset ownership to learn more. |
| | | Genentech and Gilead veteran Ramona Doyle, M.D., has become the new chief medical officer at antifibrotic biotech Blade Therapeutics. Statement Cancer and autoimmune biotech Argenx has got the second of two preclinical biobucks milestone payments under its deal with Leo Pharma. Release BlackThorn Therapeutics has been awarded a new grant, potentially worth up to $8 million, from the National Institute of Neurological Disorders and Stroke out of the NIH to support the company's development of kappa opioid receptor antagonists. Statement | |
|
Resources Sponsored By: Envigo Discover the factors that contribute to differential radiation sensitivity between the Rag2 and SCID models. Presented by: Veeva Hear three innovative leaders explain how regulatory can “go digital” in their operations by leveraging the data-handling capabilities in their RIM systems. Sponsored by Envigo Performing a sophisticated surgery to create a myocardial infarction model. Join us on June 7th at 11:00 AM EDT. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored By: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. |
|
